Wound Care Company Launches Innovative Hemostatic Dressing Kit To Stop Bleeding

Axio announced that their cutting-edge hemostatic product Axiostat has been officially approved by the USFDA thus could soon be available for private, commercial and institutional clients in the US.

Bangalore, India - July 9, 2018 /NewsNetwork/ —

Axio, a company specializing in cutting-edge wound care products, launched Axiostat, an FDA-approved chitosan-based wound dressing designed to stop profuse bleeding. Using a novel biomaterial platform, Axiostat forms a mechanical seal through its bio-adhesive properties, thus stopping bleeding much more quickly than conventional cotton gauze.

More information can be found at https://www.axiobio.com.

The most widely used means of stopping bleeding is standard cotton gauze, a potentially inefficient solution against profuse bleeding. Studies show that more than 1.25 million people die each year due to severe bleeding following auto accidents, making it essential for health care providers to invest in a more efficient hemostatic solution.

Axiostat, the innovative wound dressing product developed by Axio Biosolutions, has now officially been approved by the USFDA and the CE, making it the most efficient hemostatic solution currently available to the public.

The wound dressing is based on chitosan, a substance obtained from treating the shell of shrimp and other crustaceans. Axiostat is highly bio-adhesive, quickly forming a barrier which prevents blood loss by concentrating plasma, protein and cellular components at the wound site.

Axiostat has various applications for successful use in different fields, including vascular, dental, emergency trauma and military healthcare. The product is currently the standard homeostatic solution of defense forces throughout the world, including the Indian Armed Forces, having helped save numerous lives in military and civilian emergencies. Axio is also developing various kits for industries and automobiles along with Rapid Prototype partners – MakeIn3D.

Leo Mavely, the CEO and founder of Axio Biosolutions, said: “The FDA clearance of Axiostat in the US is a major milestone in our journey so far. This is a validation of the performance, safety and efficacy of Axiostat in bleeding control. We developed Axiostat to be a world-class quality product and this clearance reiterates that. We could not have done it without the trust and support of our entire team as well as investors.”

Interested parties can find more information by visiting the above-mentioned website.

Contact Info:
Name: Axiobio
Email: [email protected]
Organization: Axiobio
Address: #541, 5th main, 16th cross, Indiranagar 2nd stage,, Bangalore, Bangalore 560038, India
Phone: +91-88607-86067

For more information, please visit https://www.axiobio.com/

Source: NewsNetwork

Release ID: 373650